AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29428178 — intervention group
Group type: EXPERIMENTAL
Intervention: qHPV vaccine
Number of subjects: 468
Study 29428178 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dose regimen of qHPV vaccine
Number of subjects: 468
Study 29428183 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass azithromycin treatment (coverage rate of 84%)
Number of subjects: 16092
Study 29428183 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass azithromycin treatment
Number of subjects: 16092
Study 29428438 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition (BMI <5% for age or weight-for-length <5% for <2 years)
Number of subjects: 904
Study 29428438 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI >95% for age or weight-for-length >95% for <2 years)
Number of subjects: 904
Study 29428438 — intervention group
Group type: COMPARATOR
Intervention: Normal bodyweight (NB)
Number of subjects: 904
Study 29428572 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 6623
Study 29428788 — intervention group
Group type: EXPERIMENTAL
Intervention: N.I.R. H.E.G. neurofeedback training
Number of subjects: 6
Study 29428999 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 62
Study 29429017 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-field digital mammography (FFDM) plus digital breast tomosynthesis (DBT)
Number of subjects: 24301
Study 29429017 — intervention group
Group type: COMPARATOR
Intervention: Full-field digital mammography (FFDM) alone
Number of subjects: 24301
Study 29429807 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 41385
Study 29429807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41385
Study 29429815 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-VC (2nd booster dose)
Number of subjects: 0
Study 29429815 — intervention group
Group type: COMPARATOR
Intervention: JE-MB (1st booster dose)
Number of subjects: 0
Study 29429815 — intervention group
Group type: COMPARATOR
Intervention: JE-VC (1st booster dose)
Number of subjects: 0
Study 29430250 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity extracorporeal shock wave therapy (5 outpatient sessions)
Number of subjects: 710
Study 29430278 — intervention group
Group type: EXPERIMENTAL
Intervention: H-AVA group
Number of subjects: 0
Study 29430278 — intervention group
Group type: EXPERIMENTAL
Intervention: L-AVA group
Number of subjects: 0
Study 29430278 — intervention group
Group type: EXPERIMENTAL
Intervention: AVA-B
Number of subjects: 0
Study 29430278 — intervention group
Group type: EXPERIMENTAL
Intervention: AVA-A
Number of subjects: 0
Study 29430278 — intervention group
Group type: EXPERIMENTAL
Intervention: AVA-C
Number of subjects: 0
Study 29430306 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 6
Study 29430747 — intervention group
Group type: EXPERIMENTAL
Intervention: Global left atrial strain (LA-GS) measurement
Number of subjects: 86
Study 29430747 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom severity assessment
Number of subjects: 86
Study 29430747 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic and hemodynamic parameters measurement
Number of subjects: 86
Study 29431103 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal-pro-b-type natriuretic peptide (NT-proBNP) levels at baseline
Number of subjects: 686
Study 29431128 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-intensity PA
Number of subjects: 425
Study 29431128 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity PA
Number of subjects: 425
Study 29431128 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity PA
Number of subjects: 425
Study 29431128 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting PA guidelines
Number of subjects: 425
Study 29431735 — intervention group
Group type: EXPERIMENTAL
Intervention: Vhl-deficient osteoblasts
Number of subjects: 0
Study 29431735 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment with dichloroacetate (DCA)
Number of subjects: 0
Study 29431878 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct volume on diffusion-weighted imaging on day 0
Number of subjects: 61
Study 29431878 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct volume on FLAIR on day 6
Number of subjects: 61
Study 29431878 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 61
Study 29431878 — intervention group
Group type: EXPERIMENTAL
Intervention: NIH Stroke Scale score on admission/discharge
Number of subjects: 61
Study 29431878 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion volumes on FLAIR on day 6
Number of subjects: 61
Study 29431878 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphagia
Number of subjects: 61
Study 29431878 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct location
Number of subjects: 61
Study 29432037 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive neuroscience-based interventions in school settings
Number of subjects: 0
Study 29432077 — intervention group
Group type: EXPERIMENTAL
Intervention: DNX-2401 (Delta-24-RGD)
Number of subjects: 37
Study 29432154 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxetumomab pasudotox (Moxe)
Number of subjects: 0
Study 29432378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass with a more than 40% pressure drop below normal age-standardised mean arterial pressure for 19.5 minutes
Number of subjects: 72
Study 29432378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass with a more than 50% pressure drop for 5.4 minutes
Number of subjects: 72
Study 29432378 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining perfusion pressure above 60% of normal age-standardised mean arterial pressure
Number of subjects: 72
Study 29432402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous access performance scale
Number of subjects: 48
Study 29432402 — intervention group
Group type: EXPERIMENTAL
Intervention: Team Average Performance Assessment Scale
Number of subjects: 48
Study 29432402 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Assessment Tool for leaders
Number of subjects: 48
Study 29432402 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Teamwork Scale
Number of subjects: 48
Study 29432402 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported stress
Number of subjects: 48
Study 29432402 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-confidence
Number of subjects: 48
Study 29432402 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissatisfaction
Number of subjects: 48
Study 29432402 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress markers (salivary cortisol, heart rate, pNN50, low- and high-frequency ratio)
Number of subjects: 48
Study 29432968 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Number of subjects: 0
Study 29433525 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol-SR
Number of subjects: 320
Study 29433525 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol-IR
Number of subjects: 320
Study 29433560 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-treated T1DM patients
Number of subjects: 2348
Study 29433560 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-treated T2DM patients
Number of subjects: 2348
Study 29433573 — intervention group
Group type: EXPERIMENTAL
Intervention: GH-treated patients (GH dose 0.30±0.16 mg/day for females and 0.25±0.10 mg/day for males)
Number of subjects: 106
Study 29433573 — intervention group
Group type: COMPARATOR
Intervention: Untreated GHD controls
Number of subjects: 106
Study 29434012 — intervention group
Group type: EXPERIMENTAL
Intervention: I-STAND intervention (personal coaching + Jawbone UP band)
Number of subjects: 60
Study 29434012 — intervention group
Group type: COMPARATOR
Intervention: Healthy living intervention (control)
Number of subjects: 60
Study 29434012 — intervention group
Group type: EXPERIMENTAL
Intervention: I-STAND intervention
Number of subjects: 60
Study 29434016 — intervention group
Group type: EXPERIMENTAL
Intervention: Text intervention (Coachtext)
Number of subjects: 42
Study 29434016 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice Assist intervention (MyCoach)
Number of subjects: 42
Study 29434016 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 29434460 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 29434547 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 36
Study 29434547 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 36
Study 29434547 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS with high motivation
Number of subjects: 36
Study 29434547 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation to quit (baseline and follow-up)
Number of subjects: 36
Study 29435343 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithm (MLA) for severe sepsis prediction
Number of subjects: 142
Study 29435343 — intervention group
Group type: COMPARATOR
Intervention: Current severe sepsis detector
Number of subjects: 142
Study 29435359 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib monotherapy (5 mg and 10 mg twice daily)
Number of subjects: 4967
Study 29435359 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib combination therapy (5 mg and 10 mg twice daily)
Number of subjects: 4967
Study 29435359 — intervention group
Group type: EXPERIMENTAL
Intervention: Mono→combo switchers
Number of subjects: 4967
Study 29435359 — intervention group
Group type: EXPERIMENTAL
Intervention: Combo→mono switchers
Number of subjects: 4967
Study 29435359 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib monotherapy and combination therapy
Number of subjects: 4967
Study 29435360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous abatacept
Number of subjects: 2350
Study 29435364 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0
Study 29435364 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 0
Study 29435364 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg and 75 mg
Number of subjects: 0
Study 29435364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29435776 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagliptin 100 mg orally twice per day
Number of subjects: 300
Study 29435776 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 50 mg orally once per day
Number of subjects: 300
Study 29435872 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy with weekly paclitaxel (50 mg/m²) and carboplatin, radiation therapy (50.4 Gy/28 Fx or 61.2 Gy/34 Fx)
Number of subjects: 65
Study 29435872 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin
Number of subjects: 65
Study 29436490 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation
Number of subjects: 69
Study 29437243 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment
Number of subjects: 0
Study 29437243 — intervention group
Group type: COMPARATOR
Intervention: Control (Cigarette smoking without melatonin)
Number of subjects: 0
Study 29437592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 132
Study 29437593 — intervention group
Group type: EXPERIMENTAL
Intervention: Current immunosuppressive therapies for SR-aGVHD
Number of subjects: 0
Study 29437596 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 12365
Study 29437753 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumour DNA (ctDNA) detection after surgery
Number of subjects: 0
Study 29437753 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex assay based on circulating single-molecule amplification and resequencing technology (cSMART)
Number of subjects: 0
Study 29437866 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV diagnosis
Number of subjects: 640
Study 29437935 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrel vascular reconstruction device (Barrel VRD)
Number of subjects: 20
Study 29437944 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of emphysema (LAA%)
Number of subjects: 1817
Study 29437944 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of emphysema (LAA%)
Number of subjects: 1817
Study 29437944 — intervention group
Group type: EXPERIMENTAL
Intervention: Emphysema progression
Number of subjects: 1817
Study 29438080 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA-induced thrombolysis with recombinant DNAse 1
Number of subjects: 108
Study 29438080 — intervention group
Group type: COMPARATOR
Intervention: tPA-induced thrombolysis alone
Number of subjects: 108
Study 29438139 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 kV
Number of subjects: 235
Study 29438139 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 kV
Number of subjects: 235
Study 29438139 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 kV
Number of subjects: 235
Study 29438139 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 235
Study 29438269 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair Climbing (SC)
Number of subjects: 41
Study 29438269 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control
Number of subjects: 41
Study 29438361 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0424 (5 mg to 150 mg once-daily or 40 mg bi-daily)
Number of subjects: 41
Study 29438361 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0424 (doses above 60 mg per day)
Number of subjects: 41
Study 29438361 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0424
Number of subjects: 41
Study 29438475 — intervention group
Group type: EXPERIMENTAL
Intervention: T2Candida
Number of subjects: 152
Study 29438475 — intervention group
Group type: COMPARATOR
Intervention: Companion cultures (cBCs)
Number of subjects: 152
Study 29438522 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma RAS analysis using next-generation sequencing (NGS) and methylation digital PCR
Number of subjects: 425
Study 29438522 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma RAS analysis in patients with detectable ctDNA
Number of subjects: 425
Study 29438522 — intervention group
Group type: EXPERIMENTAL
Intervention: NGS alone in patients with liver metastases
Number of subjects: 425
Study 29438522 — intervention group
Group type: EXPERIMENTAL
Intervention: NGS plus methylated biomarkers in patients with liver metastases
Number of subjects: 425
Study 29438522 — intervention group
Group type: COMPARATOR
Intervention: Absence of liver metastases
Number of subjects: 425
Study 29438525 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Number of subjects: 0
Study 29438982 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating microRNAs
Number of subjects: 64
Study 29439003 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary lifestyle factors
Number of subjects: 320
Study 29439003 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour necrosis factor inhibitors (TNFi)
Number of subjects: 320
Study 29439003 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline assessments (patient-reported outcome measures, clinical assessments of disease activity, quality of life, lifestyle)
Number of subjects: 320
Study 29439003 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 14-16 weeks after treatment initiation
Number of subjects: 320
Study 29439084 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP1A2 activity measured after administration of caffeine
Number of subjects: 126
Study 29439084 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2B6 activity measured after administration of bupropion
Number of subjects: 126
Study 29439084 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C9 activity measured after administration of tolbutamide
Number of subjects: 126
Study 29439084 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 activity measured after administration of omeprazole
Number of subjects: 126
Study 29439084 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 activity measured after administration of dextromethorphan
Number of subjects: 126
Study 29439084 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2E1 activity measured after administration of chlorzoxazone
Number of subjects: 126
Study 29439084 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A4/5 activity measured after administration of midazolam
Number of subjects: 126
Study 29439160 — intervention group
Group type: EXPERIMENTAL
Intervention: depression-executive dysfunction syndrome (DES)
Number of subjects: 245
Study 29439160 — intervention group
Group type: EXPERIMENTAL
Intervention: co-occurrence of ED and PSD
Number of subjects: 245
Study 29439186 — intervention group
Group type: EXPERIMENTAL
Intervention: BGB-3111 and PD-1 antibody
Number of subjects: 0
Study 29439670 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation DNA vaccine targeting antigen-presenting cells (APCs) with a sequence encoding a chemokine (MIP-3α)
Number of subjects: 0
Study 29439670 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation DNA vaccine
Number of subjects: 0
Study 29439684 — intervention group
Group type: EXPERIMENTAL
Intervention: PACD scores on day 1
Number of subjects: 1896
Study 29439684 — intervention group
Group type: EXPERIMENTAL
Intervention: PACD scores on day 3
Number of subjects: 1896
Study 29439684 — intervention group
Group type: EXPERIMENTAL
Intervention: PACD scores on day 1 for neurological patients
Number of subjects: 1896
Study 29439684 — intervention group
Group type: EXPERIMENTAL
Intervention: PACD scores on day 3 for neurological patients
Number of subjects: 1896
Study 29439707 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 427
Study 29439707 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 427
Study 29439857 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg orally twice per day plus pembrolizumab 2 mg/kg intravenously every 3 weeks
Number of subjects: 52
Study 29439857 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 52
Study 29439971 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg/day) and Ribavirin (1,000 to 1,200 mg/day) for 3 to 52 weeks
Number of subjects: 30
Study 29439971 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Number of subjects: 30
Study 29439971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 30
Study 29440006 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher apoB/apoA-I ratio in younger patients
Number of subjects: 159
Study 29440006 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherogenic lipid factors
Number of subjects: 159
Study 29440006 — intervention group
Group type: COMPARATOR
Intervention: Older patients
Number of subjects: 159
Study 29440043 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 592
Study 29440043 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 592
Study 29440043 — intervention group
Group type: EXPERIMENTAL
Intervention: No clear preference
Number of subjects: 592
Study 29440123 — intervention group
Group type: EXPERIMENTAL
Intervention: Health status outcomes including symptoms, functional status, and quality of life
Number of subjects: 1275
Study 29440123 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments at 3, 6, and 12 months
Number of subjects: 1275
Study 29440123 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical follow-up for PAD-related hospitalizations and major cardiovascular events
Number of subjects: 1275
Study 29440154 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional surgical treatment (full sternotomy)
Number of subjects: 16
Study 29440154 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical treatment
Number of subjects: 16
Study 29440154 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter surgical treatment
Number of subjects: 16
Study 29440275 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior PCI
Number of subjects: 3641
Study 29440275 — intervention group
Group type: COMPARATOR
Intervention: Control (No prior PCI)
Number of subjects: 3641
Study 29440404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) for 4 weeks, intensive daily sessions.
Number of subjects: 0
Study 29440410 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiecho fMRI techniques
Number of subjects: 0
Study 29440587 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphism (rs35705950) in mucin 5B
Number of subjects: 0
Study 29440587 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29441116 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipjeondaebo-tang (3g, 3 times a day for 4 weeks)
Number of subjects: 32
Study 29441116 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 times a day for 4 weeks)
Number of subjects: 32
Study 29441642 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycra splinting socks
Number of subjects: 9
Study 29441642 — intervention group
Group type: COMPARATOR
Intervention: Lycra splinting shorts or leggings
Number of subjects: 9
Study 29442437 — intervention group
Group type: EXPERIMENTAL
Intervention: ID3 missense variant (rs11574-A)
Number of subjects: 10359
Study 29442437 — intervention group
Group type: COMPARATOR
Intervention: Control group (no genetic variant)
Number of subjects: 10359
Study 29442440 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Treatment (BT)
Number of subjects: 0
Study 29443701 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy (5 or more unique medications)
Number of subjects: 266499
Study 29443701 — intervention group
Group type: COMPARATOR
Intervention: No polypharmacy (fewer than 5 unique medications)
Number of subjects: 266499
Study 29443701 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy
Number of subjects: 266499
Study 29443701 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk medications
Number of subjects: 266499
Study 29443701 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriptions filled in the 30 preoperative days
Number of subjects: 266499